MedDataX Logo

Monitoring and Rehabilitation for ICIACI Rehabilitation：A Cohort Study

NCT07278817 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 340

Last updated 2025-12-12

No results posted yet for this study

Summary

Immune checkpoint inhibitor-associated cardiac injury (ICIACI) is a low-incidence but highly fatal adverse event. A significant knowledge gap exists regarding the disease characteristics and recovery status of patients during the ICIACI convalescent phase. The objectives of this study are to establish a national, multicenter cohort for this patient population and to comprehensively describe their clinical profiles from an integrated Traditional Chinese and Western medicine standpoint, as well as their current rehabilitation status.

Conditions

  • Immune Checkpoint Inhibitor-Related Myocarditis

Sponsors & Collaborators

  • Weifang Hospital of Traditional Chinese Medicine

    collaborator UNKNOWN

  • Chinese Academy of Medical Sciences, Fuwai Hospital

    collaborator OTHER

  • Second Affiliated Hospital of Nanchang University

    collaborator OTHER

  • China-Japan Friendship Hospital

    lead OTHER

Principal Investigators

  • Jingyi Ren, Professor · China-Japan Friendship Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-30
Primary Completion
2028-07-31
Completion
2028-07-31

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07278817 on ClinicalTrials.gov